💫 Check out the new article in the inaugural issue of the new EANM Journal: EANM insights on PET-based response assessment in neuro-oncology: things are moving forward! doi.org/10.1016/j.ea... @eanm.org

We’re thrilled to see so many high-quality submissions coming in for our journals! 🎉 Explore the latest publications and the editorials written by our EANM Board and Editors-in-Chief: 👉 The EANM Journal: sciencedirect.com/journal/the-... 👉 EANM Innovation: sciencedirect.com/journal/eanm...

🚨New paper in EJNMMI: [177Lu]Lu-DOTATATE for refractory meningiomas: factors associated with the therapeutic response and initial tumor dosimetric data. link.springer.com/article/10.1...

Who’s ready for 2025 WFNOS/SNO Annual meeting in Honolulu?! Register by Sept 19 to get early bird pricing and join colleagues from around the world in advancing #neurooncology. soc-neuro-onc.org/SNO2025

🧠 EANS-EANO Guidelines on the extent of resection in gliomas. academic.oup.com/neuro-oncolo... @eanoassociation.bsky.social @neuroonc.bsky.social

🚨 💫 Happy to share that that @eortc.org is a 🙌 collaboration partner for the #NMN2026 Symposium: www.nmn-society.org! @nathaliealbert.bsky.social

🚨 New publication in Journal of Nuclear Medicine: Retrospective Evaluation of the Correlation Between Somatostatin Receptor PET/CT and Histopathology in Patients with Suspected Intracranial Meningiomas. jnm.snmjournals.org/content/earl...

🌎 ☢️ 🩺 Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access. www.sciencedirect.com/science/arti...

New publication in Nature Reviews Clinical Oncology: The molecular blueprint of targeted radionuclide therapy. www.nature.com/articles/s41...

Prognostic value of [18F]FET-PET in diffuse low-grade (grade 2) gliomas after the 2021 classification of CNS tumors. link.springer.com/article/10.1...

Assessment of 18F-FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria. academic.oup.com/noa/advance-...

🚨 Registration deadline for the EACR conference on #cancerneuroscience is September 15 ‼️ Please join us in beautiful Bilbao for exciting discussions on the dialogue between the nervous system and cancer 🔬🧠 See you soon!

Tumor Versus Capillary Telangiectasia in Recurring Glioblastoma. journals.lww.com/nuclearmed/f... @nathaliealbert.bsky.social

Thank you! We're pleased to support the #NMN2026 Symposium and collaborate with colleagues across the global neuro-oncology community. 🌐🧠 #EANO #Collaboration #NeuroOncology

Prediction of progression-free and overall survival following temozolomide chemoradiation using FET PET-based parameters including radiomics in patients with glioblastoma. academic.oup.com/noa/advance-...

🤩 Happy to share that the EANO is endorsing the #NMN2026 Symposium: www.nmn-society.org! 💫 Excited to join forces with the leading mulitdisciplinary neuro-oncology society in Europe 🌎 ! www.eano.eu @eanoassociation.bsky.social @nathaliealbert.bsky.social @michael-platten.bsky.social

Spatial tumour characteristics as an indirect marker of metabolic dysregulation: evaluation for non-invasive IDH-genotyping of glioma using hybrid [18 F]FET-PET/MRI. link.springer.com/article/10.1...

⭐️New Article published at Nature Cancer! 'Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling' ✒️By Wies Vallentgoed and colleagues 🔗 www.nature.com/articles/s43...

Convection-enhanced delivery of [225Ac]Ac-DOTA-SP in recurrent glioblastoma – tumour uptake. link.springer.com/article/10.1...

🔥 Hot off the press in Neuro-Oncology by @mj-mair.bsky.social et al: Prognostic stratification of newly diagnosed IDH-mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET – a retrospective, bicentric cohort study. academic.oup.com/neuro-oncolo... @eanoassociation.bsky.social

Early seizure freedom with [18F]fluorodopa positron emission tomography response after isocitrate dehydrogenase inhibition with vorasidenib: First case report. onlinelibrary.wiley.com/doi/full/10....

The role of amino acid PET in the era of checkpoint inhibitors and targeted therapy for brain tumor treatment. journals.lww.com/co-neurology...

🧠 Just published in Neuro-Oncology: A comprehensive consensus review by @neuroonc.bsky.social and EANO on current management and future directions in adult #Glioblastoma care. Explore key recommendations and research priorities. 🔗 academic.oup.com/neuro-oncolo... #NeuroOncology

The use of minor response, volumetric assessment, and growth rate kinetics as endpoints in grade 1-3 glioma clinical trials: a RANO perspective. academic.oup.com/neuro-oncolo... @eanoassociation.bsky.social @neuroonc.bsky.social

Have you read the new edition of our #ICOM newsletter? In it, you can read about the latest #meningioma-related events and articles from our members. adobe.ly/45yJe1R

🔥 Hot of the press in Neuro-Oncology! 🧠 #Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. academic.oup.com/neuro-oncolo... @eanoassociation.bsky.social @neuroonc.bsky.social

🤩 Happy to share that the Asian Society for Neuro-Oncology (ASNO) is endorsing the #NMN2026 Symposium: www.nmn-society.org! 🌎 Looking forward to this collaboration to advance Nuclear Medicine and Neuro-Oncology on a global level! www.a-sno.org @nathaliealbert.bsky.social

🔥 Hot off the press in JNM: [177Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1, EORTC-2334-BTG): Study Protocol for a Randomized Phase II Trial. 🩺 Study enrollment is ongoing. jnm.snmjournals.org/content/earl... @nathaliealbert.bsky.social @journalofnucmed.bsky.social @eortc.org

EANO and @neuroonc.bsky.social welcome @wickwolfgang.bsky.social, MD as the new Editor-in-Chief of Neuro-Oncology Advances! Thanks to @gelarehzadeh.bsky.social for seven years of outstanding leadership. Exciting new chapter ahead! #NeuroOncology #EANO #SNO #NeuroOncologyAdvances

🥳 🙌 Happy to report that the Response Assessment in Neuro-Oncology (RANO) group is endorsing the #NMN2026 Symposium: www.nmn-society.org. 🤩 🌎 Check out the RANO achievements 2009-2025: academic.oup.com/neuro-oncolo...! @eanoassociation.bsky.social @neuroonc.bsky.social @nathaliealbert.bsky.social

🤩 Proud to announce that @neuroonc.bsky.social is officially endorsing the #NMN2026 Symposium and will be represented by Erik Sulman in the meeting faculty! 🧠 🌎 Join us on May 07/08th 2026 in Vienna: www.nmn-society.org. www.soc-neuro-onc.org @nathaliealbert.bsky.social @chashaynes.bsky.social

🧠 Just published in @thelancetoncol.bsky.social: Updated RANO and EANO recommendations on the clinical use of PET imaging in gliomas. 🔗 Read more: www.thelancet.com/journals/lan... #NeuroOncology #Glioma #PETimaging #EANO #RANO #BrainTumor #LancetOncology

🔥 Hot off the press in Lancet Oncology: Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas. authors.elsevier.com/sd/article/S... @galldiks.bsky.social @nathaliealbert.bsky.social @eanoassociation.bsky.social @neuroonc.bsky.social

HER3-targeted patritumab deruxtecan showed efficacy in leptomeningeal metastases from solid tumors in the Phase II TUXEDO-3 trial 📉 65% 3-month survival 🧬 Activity in intracranial lesions 🔷 From Matthias Preusser, MD, et al 🔗 ascopost.com/news/july-20...

Biological tumor volume predicts survival in recurrent High-Grade glioma: A multiparametric [18F]FET PET/MRI study. link.springer.com/article/10.1... @eanm.org

Update to the RANO Working Group and EANO recommendations for the clinical use of PET imaging in gliomas. academic.oup.com/neuro-oncolo... @neuroonc.bsky.social @eanoassociation.bsky.social @nathaliealbert.bsky.social @galldiks.bsky.social

🌍 Full text access to the PET RANO BM 1.0 criteria for response assessment of brain metastases based on amino acid PET imaging: rdcu.be/ew8m0.

🗓️ ✏️ Mark your calendar for #NMN2026! 💫 We have chosen another fantastic venue in Vienna for the next edition of the "Nuclear Medicine Meets Neuro-Oncology" Symposium to be held on May 07/08th 2026 in Vienna! 🌎 www.nmn-society.org @nathaliealbert.bsky.social @eanoassociation.bsky.social @eortc.org

🌍 Today is #glioblastomaday. 🤝 Everyday Nuclear Medicine and Neuro-Oncology are jointly working to improve diagnosis and therapy for patients with glioblastoma through research and education. 💫

🧠New publication from the EORTC-BTG-1320 trial: Discover how advanced imaging metrics could improve prognostic accuracy in neuro-oncology. 👇 🔗 Read more: www.eortc.org/bibliography/ #NeuroOncology #Meningioma #EORTCbrain #CancerResearch

Prognostic value of 1D, 2D and volumetric tumor size increases in recurrent WHO grade 2 and 3 meningiomas: radiological post-hoc analysis of the EORTC-BTG-1320 trial. academic.oup.com/noa/advance-... @eortc.org

📣 Call for Mentors: EANO Mentorship Program! Help shape the next generation of #NeuroOncology experts! EANO seeks experienced clinicians & researchers (basic science, AHP, medical) as volunteer mentors. 🗓 Deadline: July 31, 2025 👉 Apply: www.eano.eu/eano-youngst... #EANO #Mentorship

🤩 Online now: check out the fotos and impressions 📸 from #NMN2025 - where Nuclear Medicine and Neuro-Oncology met to advance molecular imaging and theranostics for patients with brain tumors! 🚀 www.nmn-society.org/past-events/

🧠 New EORTC survey shows PET imaging is widely available and used across European brain tumour centres. With data from 103 centres in 20 countries, the findings support PET-based endpoints in future trials. 🔗 Find out more: www.eortc.org/blog/2025/07... #EORTCbrain #PETImaging

[18F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trial. rdcu.be/etoGe

🚨 Apply now for the NMN Clinical tRiaLisT Fellowship and learn how to make an impact through clinical trials on theranostics for brain tumors! 🧠 www.nmn-society.org/clinical-tri... @nathaliealbert.bsky.social

💫 🌍 Availability and use of PET in patients with brain tumours – a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) survey. link.springer.com/article/10.1... @mj-mair.bsky.social @nathaliealbert.bsky.social @eortc.org @eanoassociation.bsky.social

🥁 Breaking News Editorial on the TUXEDO-3 trial published in Neuro-Onology. academic.oup.com/neuro-oncolo... @neuroonc.bsky.social

Live from #ASCO25 in Chicago: presentation of latest results on HER3-DXd efficacy and safety in patients with leptomeningeal metastatic disease of solid tumors - with simultaneous publication in Nature Medicine. Learn more: doi.org/10.1038/s415... #NeuroOncology